A Phase 2 interventional study of INS018_055 and Placebo in Idiopathic Pulmonary Fibrosis (IPF), sponsored by InSilico Medicine Hong Kong Limited. Completed at 22 sites in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by InSilico Medicine Hong Kong Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.
Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 35th largest by enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2023, is one of 21 in phase 2, and was the 29th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:
InSilico Medicine Hong Kong Limited · Sites in China
Ages 40+
AstraZeneca · Sites in China, United States, Argentina and 20 more countries
Ages 40+
Dragonboat Biopharmaceutical Company Limited · Sites in China
Ages 40+
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine · Sites in China
Ages 40–85
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 24 · Phase 3 14
First in 2012; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 83 across the 60 interventional studies, 310 across the 7 observational. Of the 33 that completed or were terminated, 11 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 67 have an industry lead sponsor. The 10 most frequent:
InSilico Medicine Hong Kong Limited is the lead sponsor of 12 studies on the registry; 9 are open to participants now.
InSilico Medicine Hong Kong Limited has 4 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Idiopathic Pulmonary Fibrosis with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06125327Phase 3Guangzhou JOYO Pharma Co., LtdSC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | 2026-12-31 |
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT06267183Shanghai Synvida Biotechnology Co.,Ltd.A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers. | 2026-11-30 |
| NCT07820254Shanghai Pulmonary Hospital, Shanghai, ChinaInspiratory Flow Rate Capability in Pulmonary Fibrosis Patients | 2026-12-31 |
| NCT07121413Shanghai Synvida Biotechnology Co.,Ltd.A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF).
The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meeting all of the following criteria during the screening period:
Exclusion Criteria:
Other protocol inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group 1: INS018\_055 once daily up to 12 weeks, low dose
Drug: INS018_055
Group 2: INS018\_055 twice daily up to 12 weeks, low dose
Drug: INS018_055
Group 3: INS018\_055 once daily up to 12 weeks, high dose
Drug: INS018_055
Group 4: Placebo once or twice daily up to 12 weeks
Drug: Placebo
Pharmaceutical formulation: Capsules Mode of Administration: Oral
Pharmaceutical formulation: Capsules Mode of Administration: Oral
Percentage of Participants Who Had at Least 1 Treatment-emergent Adverse Event (TEAE)
TEAEs were either events with start date on or after the start of the Treatment Period and up to 17 days after EOT (end of treatment), or events with start date prior to the start of the Treatment Period whose severity worsened on or after the start of the Treatment Period and up to 17 days after EOT. CTCAE=Common Terminology Criteria for Adverse Events
Time frame: From first dose of study drug until end of study (EOS) visit i.e. up to 13 weeks (+10 days)
Relative Change From Baseline in Forced Vital Capacity (FVC)
Decline (change) in FVC is presented from Week 0 to Week 12. FVC was assessed using standardized spirometry equipment.
Time frame: Week 0/Visit 2 up to Week 12
Absolute Change From Baseline in FVC in L
Decline (change) in FVC is presented from Week 0 to Week 12. FVC was assessed using standardized spirometry equipment.
Time frame: Week 0/Visit 2 up to Week 12
Absolute Change in FVC % Predicted
Absolute change in FVC % predicted from Week 0 to Week 12 is presented. FVC was assessed using standardized spirometry equipment
Time frame: Week 0/Visit 2 up to Week 12
Relative Change in FVC % Predicted
Relative change in FVC % predicted from Week 0 to Week 12 is presented. FVC was assessed using standardized spirometry equipment
Time frame: Week 0/Visit 2 up to Week 12
| Milestone | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo |
|---|---|---|---|---|
| Started | 18 | 18 | 18 | 17 |
| Completed | 16 | 14 | 13 | 16 |
| Not completed | 2 | 4 | 5 | 1 |
| Withdrew: Adverse event | 1 | 3 | 2 | 1 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Participant asked to withdraw from the trial | 1 | 0 | 0 | 0 |
| Withdrew: Participant withdrew from treatment and refused to do visit 7 follow up visit | 0 | 0 | 1 | 0 |
| Withdrew: Participant refused to come in | 0 | 0 | 1 | 0 |
TEAEs were either events with start date on or after the start of the Treatment Period and up to 17 days after EOT (end of treatment), or events with start date prior to the start of the Treatment Period whose severity worsened on or after the start of the Treatment Period and up to 17 days after EOT. CTCAE=Common Terminology Criteria for Adverse Events
| Participants | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo |
|---|---|---|---|---|
| Any TEAE | 13 | 15 | 15 | 12 |
| TEAE with CTCAE grade ≥3 | 3 | 7 | 8 | 4 |
| TEAE Leading to discontinuation of treatment | 1 | 5 | 4 | 2 |
| TEAE Leading to death | 0 | 1 | 0 | 0 |
Decline (change) in FVC is presented from Week 0 to Week 12. FVC was assessed using standardized spirometry equipment.
| percentage change in FVC | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo |
|---|---|---|---|---|
| Relative Change From Baseline in Forced Vital Capacity (FVC) | -0.7923 ± 3.90508 | 0.6821 ± 6.09585 | 3.2253 ± 5.27457 | -0.7126 ± 8.17452 |
Decline (change) in FVC is presented from Week 0 to Week 12. FVC was assessed using standardized spirometry equipment.
| L | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo |
|---|---|---|---|---|
| Absolute Change From Baseline in FVC in L | -0.0270 ± 0.11368 | 0.0197 ± 0.14177 | 0.0984 ± 0.14113 | -0.0203 ± 0.18300 |
Absolute change in FVC % predicted from Week 0 to Week 12 is presented. FVC was assessed using standardized spirometry equipment
| Percent predicted | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo |
|---|---|---|---|---|
| Absolute Change in FVC % Predicted | -0.6729 ± 2.92554 | 0.6455 ± 3.73482 | 3.0461 ± 4.38853 | -0.5675 ± 5.44712 |
Relative change in FVC % predicted from Week 0 to Week 12 is presented. FVC was assessed using standardized spirometry equipment
| Percent predicted | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo |
|---|---|---|---|---|
| Relative Change in FVC % Predicted | -0.6724 ± 4.05537 | 0.4434 ± 5.96895 | 3.2194 ± 5.28129 | -0.8414 ± 8.31651 |
Collected over Adverse events (AEs) were collected from the signing of the informed consent form (ICF) until end of study (EOS) visit i.e. up to 13 weeks (+10 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| INS018_055 30 mg QD | 0/18 (0%) | 2/18 (11.1%) | 13/18 (72.2%) |
| INS018_055 30 mg BID | 1/18 (5.6%) | 4/18 (22.2%) | 15/18 (83.3%) |
| INS018_055 60 mg QD | 0/18 (0%) | 7/18 (38.9%) | 15/18 (83.3%) |
| Placebo | 0/17 (0%) | 3/17 (17.6%) | 12/17 (70.6%) |
| Event | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo |
|---|---|---|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 0/18 | 0/18 | 3/18 | 0/17 |
| PneumoniaInfections and infestations | 0/18 | 0/18 | 2/18 | 0/17 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/18 | 0/18 | 1/18 | 1/17 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/18 | 0/18 | 0/18 | 1/17 |
| Upper respiratory tract infectionInfections and infestations | 0/18 | 0/18 | 0/18 | 1/17 |
| Chronic gastritisGastrointestinal disorders | 0/18 | 0/18 | 0/18 | 1/17 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/18 | 0/18 | 1/18 | 0/17 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/18 | 0/18 | 1/18 | 0/17 |
| Liver injuryHepatobiliary disorders | 0/18 | 1/18 | 1/18 | 0/17 |
| Drug-induced liver injuryHepatobiliary disorders | 0/18 | 1/18 | 0/18 | 0/17 |
| Event | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo |
|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 1/18 | 1/18 | 6/18 | 1/17 |
| HypokalemiaMetabolism and nutrition disorders | 3/18 | 5/18 | 4/18 | 2/17 |
| DiarrhoeaGastrointestinal disorders | 2/18 | 3/18 | 5/18 | 0/17 |
| Blood bilirubin increasedInvestigations | 0/18 | 1/18 | 4/18 | 2/17 |
| Upper respiratory tract infectionInfections and infestations | 1/18 | 4/18 | 1/18 | 1/17 |
| Hepatic function abnormalHepatobiliary disorders | 2/18 | 4/18 | 3/18 | 2/17 |
| Respiratory tract infectionInfections and infestations | 0/18 | 1/18 | 2/18 | 3/17 |
| NasopharyngitisInfections and infestations | 0/18 | 0/18 | 0/18 | 2/17 |
| Aspartate aminotransferase increasedInvestigations | 1/18 | 1/18 | 2/18 | 0/17 |
| Blood lactate dehydrogenase increasedInvestigations | 0/18 | 0/18 | 2/18 | 0/17 |
Intent-to-treat (ITT) Population
| Age, Continuous(years) | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 65.8 ± 6.99 | 67.2 ± 7.77 | 65.7 ± 6.82 | 68.3 ± 5.28 | 66.7 ± 6.73 |
| Age, Customized(Participants) | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo | Total |
|---|---|---|---|---|---|
| ≤ 65 years | 9 | 7 | 7 | 4 | 27 |
| > 65 to ≤ 75 years | 7 | 9 | 10 | 13 | 39 |
| >75 years | 2 | 2 | 1 | 0 | 5 |
| Sex: Female, Male(Participants) | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo | Total |
|---|---|---|---|---|---|
| Female | 0 | 3 | 2 | 2 | 7 |
| Male | 18 | 15 | 16 | 15 | 64 |
| Ethnicity (NIH/OMB)(Participants) | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 18 | 18 | 18 | 17 | 71 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 18 | 18 | 18 | 17 | 71 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Height at Baseline(centimeters (cm)) | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 167.77 ± 5.549 | 165.78 ± 7.869 | 166.29 ± 6.470 | 164.50 ± 7.874 | 166.11 ± 6.944 |
| Weight at Baseline(kilograms (kg)) | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 72.27 ± 7.395 | 67.36 ± 12.141 | 73.32 ± 13.547 | 67.69 ± 12.117 | 70.20 ± 11.593 |
| Body Mass Index at Baseline(kg/m2) | INS018_055 30 mg QD | INS018_055 30 mg BID | INS018_055 60 mg QD | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 25.66 ± 2.080 | 24.41 ± 3.399 | 26.41 ± 4.128 | 24.96 ± 3.733 | 25.36 ± 3.429 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2023 to primary completion in Aug 2024, 13 months.
Results were first posted in Dec 2025, 1 year 3 months after primary completion.
Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 13 months is below that.
Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rentosertib
Idiopathic Pulmonary Fibrosis →
InSilico Medicine Hong Kong Limited